Eli Lilly blows past quarterly estimates posts strong outlook as Zepbound and Mounjaro sales soar…
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.